Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

PURPOSE: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. PATIENTS AND METHODS: To identify predictive biomarkers of clinical...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sabatino, Marianna, Kim-Schulze, Seunghee, Panelli, Monica C., Stroncek, David, Wang, Ena, Taback, Bret, Kim, Dae Won, DeRaffele, Gail, Pos, Zoltan, Marincola, Francesco M., Kaufman, Howard L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2009
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2689845/
https://ncbi.nlm.nih.gov/pubmed/19364969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.1106
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items